Lakeshore Biopharma Co, Stock Performance
| LSBPW Stock | 0.06 0 5.63% |
LakeShore Biopharma holds a performance score of 7 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.54, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, LakeShore Biopharma will likely underperform. Use LakeShore Biopharma Co, maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on LakeShore Biopharma Co,.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in LakeShore Biopharma Co, are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, LakeShore Biopharma showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 370.4 M |
LakeShore |
LakeShore Biopharma Relative Risk vs. Return Landscape
If you would invest 6.70 in LakeShore Biopharma Co, on December 25, 2024 and sell it today you would lose (0.33) from holding LakeShore Biopharma Co, or give up 4.93% of portfolio value over 90 days. LakeShore Biopharma Co, is currently producing 2.0869% returns and takes up 22.0069% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than LakeShore, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
LakeShore Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LakeShore Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LakeShore Biopharma Co,, and traders can use it to determine the average amount a LakeShore Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0948
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | LSBPW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 22.01 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.09 actual daily | 42 58% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average LakeShore Biopharma is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LakeShore Biopharma by adding it to a well-diversified portfolio.
LakeShore Biopharma Fundamentals Growth
LakeShore Stock prices reflect investors' perceptions of the future prospects and financial health of LakeShore Biopharma, and LakeShore Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LakeShore Stock performance.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.69) % | ||||
| Revenue | 573.42 M | ||||
| Gross Profit | 386.06 M | ||||
| EBITDA | (368.66 M) | ||||
| Net Income | (433.46 M) | ||||
| Total Debt | 424.46 M | ||||
| Book Value Per Share | 30.76 X | ||||
| Cash Flow From Operations | (295.23 M) | ||||
| Total Asset | 1.51 B | ||||
| Retained Earnings | (2.31 B) | ||||
| Working Capital | 100.94 M | ||||
About LakeShore Biopharma Performance
Evaluating LakeShore Biopharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if LakeShore Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if LakeShore Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 567.81 | 417.90 | |
| Return On Tangible Assets | (0.35) | (0.33) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.67) | (0.70) |
Things to note about LakeShore Biopharma Co, performance evaluation
Checking the ongoing alerts about LakeShore Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LakeShore Biopharma Co, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LakeShore Biopharma is way too risky over 90 days horizon | |
| LakeShore Biopharma has some characteristics of a very speculative penny stock | |
| LakeShore Biopharma appears to be risky and price may revert if volatility continues | |
| LakeShore Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| LakeShore Biopharma Co, was previously known as YSBPW Old and was traded on NASDAQ Exchange under the symbol YSBPW. | |
| The company reported the revenue of 573.42 M. Net Loss for the year was (433.46 M) with profit before overhead, payroll, taxes, and interest of 386.06 M. | |
| LakeShore Biopharma generates negative cash flow from operations | |
| LakeShore Biopharma has a frail financial position based on the latest SEC disclosures |
- Analyzing LakeShore Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LakeShore Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining LakeShore Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LakeShore Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of LakeShore Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LakeShore Biopharma's stock. These opinions can provide insight into LakeShore Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for LakeShore Stock Analysis
When running LakeShore Biopharma's price analysis, check to measure LakeShore Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LakeShore Biopharma is operating at the current time. Most of LakeShore Biopharma's value examination focuses on studying past and present price action to predict the probability of LakeShore Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LakeShore Biopharma's price. Additionally, you may evaluate how the addition of LakeShore Biopharma to your portfolios can decrease your overall portfolio volatility.